
Cigna (CI) Stock Forecast & Price Target
Cigna (CI) Analyst Ratings
Bulls say
Cigna Group is well-positioned for growth and has a positive outlook due to its strong performance in the first quarter of 2026, driven by solid specialty volume growth and continued mix shift towards higher-margin products. The company's decision to exit the Exchange business in 2027 and strategic review of EviCore show its commitment to focusing on core growth opportunities. Additionally, Cigna's strong retention and early new business wins in the 2027 Pharmacy Benefit selling season bode well for future growth. Overall, the company's aggressive share repurchase activity and expansion of its Evernorth services should support low-teens EPS growth in the near term. Risks include potential impacts from regulatory changes on rebate economics and a protracted economic downturn.
Bears say
Cigna Group is facing considerable risks, including potential government headwinds and low utilization due to contractual arrangements, which could negatively impact its growth and profitability in the short term. In addition, delays or failures in successfully integrating recent acquisitions, such as Express Scripts and VillageMD, could also hinder Cigna's long-term growth potential. Although the company has a strong focus on improving access, cost and quality of care, uncertainties surrounding political and regulatory issues pose potential risks to its sustainability efforts. These risks, along with Cigna's current valuation at a discount to its historical average, justify a negative outlook on the stock.
This aggregate rating is based on analysts' research of Cigna and is not a guaranteed prediction by Public.com or investment advice.
Cigna (CI) Analyst Forecast & Price Prediction
Start investing in Cigna (CI)
Order type
Buy in
Order amount
Est. shares
0 shares